Trial · NCT01454583
Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany
NCT01454583, Completed, Stiftung Institut fuer Herzinfarktforschung; results first posted 2014-08-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany. Trials, record NCT01454583. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01454583
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany
- NCT number
- NCT01454583
- Status
- Completed
- Enrollment
- 15,337 participants, actual
- Lead sponsor
- Stiftung Institut fuer Herzinfarktforschung
- Conditions
- Arterial Hypertension
- Interventions
- Aliskiren, ACE-I/ARB, No RAS-inhibition
- First posted
- 2011-10-19
- Last updated
- 2016-07-21
- Results first posted
- 2014-08-22
Source ClinicalTrials.gov
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP) | baseline and 1 year | Relative change of systolic office blood pressure since baseline, i.e. SBP at baseline minus SBP after 1 year, the difference divided by the baseline value, multiplied by 100 |
| Primary | Efficacy of Hypertension Treatment on Diastolic Blood Pressure (DBP) | Baseline and 1 year | Relative change of diastolic office blood pressure since baseline, i.e. DBP at baseline minus DBP after 1 year, the difference divided by the baseline value, multiplied by 100 |
| Primary | Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP) | Baseline and 2 years | Relative change of systolic office blood pressure since baseline, i.e. SBP at baseline minus SBP after 2 years, the difference divided by the baseline value, multiplied by 100 |
| Primary | Efficacy of Hypertension Treatment on Diastolic Office Blood Pressure (DBP) | Baseline and 2 years | Relative change of diastolic office blood pressure since baseline, i.e. DBP at baseline minus DBP after 1 year, the difference divided by the baseline value, multiplied by 100 |
| Primary | Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP) | Baseline and 3 years | Relative change of systolic office blood pressure since baseline, i.e. SBP at baseline minus SBP after 3 years, the difference divided by the baseline value, multiplied by 100 |
| Primary | Efficacy of Hypertension Treatment on Diastolic Blood Pressure (DBP) | Baseline and 3 years | Relative change of diastolic office blood pressure since baseline, i.e. DBP at baseline minus DBP after 3 years, the difference divided by the baseline value, multiplied by 100 |
| Secondary | Therapy Adherence Regarding Drug Treatment | Baseline and 1 year | Percentage of patients not having changed the therapy group after 1 year (DRI, ARB/ACE-I, or No-RAS-I, referring to their therapy at baseline) |
| Secondary | Therapy Adherence Regarding Drug Treatment | Baseline and 2 years | Percentage of patients not having changed the therapy group after 2 years (DRI, ARB/ACE-I, or No-RAS-I, referring to their therapy at baseline) |
| Secondary | Therapy Adherence Regarding Drug Treatment | Baseline and 3 years | Percentage of patients not having changed the therapy group after 3 years (DRI, ARB/ACE-I, or No-RAS-I, referring to their therapy at baseline) |
| Secondary | Adverse Events | 1 year follow up | Percentage of participants that experienced at least one adverse event during the first year of observation period |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 registered outcomesOutcomes21
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP) | baseline and 1 year | percent change | MEAN | |
| SECONDARY | Therapy Adherence Regarding Drug Treatment | Baseline and 1 year | percentage of patients | NUMBER | |
| SECONDARY | Therapy Adherence Regarding Drug Treatment | Baseline and 2 years | percentage of patients | NUMBER | |
| SECONDARY | Therapy Adherence Regarding Drug Treatment | Baseline and 3 years | percentage of patients | NUMBER | |
| SECONDARY | Adverse Events | 1 year follow up | percentage of patients | NUMBER | |
| SECONDARY | Adverse Events | 2 years follow up | percentage of patients | NUMBER | |
| SECONDARY | Adverse Events | 3 years follow up | percentage of patients | NUMBER | |
| SECONDARY | Therapeutic Success of Hypertension Treatment on Systolic Blood Pressure (SBP) as Measured by 24-hour Blood Pressure Measurement | Baseline and 1 year | percent change | MEAN | |
| SECONDARY | Therapeutic Success of Hypertension Treatment on Diastolic Blood Pressure (DBP) as Measured by 24-hour Blood Pressure Measurement | Baseline and 1 year | percent change | MEAN | |
| SECONDARY | Therapeutic Success of Hypertension Treatment on Systolic Blood Pressure (SBP) as Measured by 24-hour Blood Pressure Measurement | Baseline and 2 years | percent change | MEAN |
1 to 10 of 21Source ClinicalTrials.gov
See all 21 outcomesResults by group63
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP) | Group A | 11.8 | Standard Deviation 12.5 | percent change | |
| Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP) | Group B | 9.7 | Standard Deviation 12.4 | percent change | |
| Efficacy of Hypertension Treatment on Systolic Blood Pressure (SBP) | Group C | 9.9 | Standard Deviation 12.8 | percent change | |
| Therapy Adherence Regarding Drug Treatment | Group A | 92.8 | percentage of patients | ||
| Therapy Adherence Regarding Drug Treatment | Group B | 94.9 | percentage of patients | ||
| Therapy Adherence Regarding Drug Treatment | Group C | 85.0 | percentage of patients | ||
| Therapy Adherence Regarding Drug Treatment | Group A | 85.2 | percentage of patients | ||
| Therapy Adherence Regarding Drug Treatment | Group B | 89.7 | percentage of patients | ||
| Therapy Adherence Regarding Drug Treatment | Group C | 72.5 | percentage of patients | ||
| Therapy Adherence Regarding Drug Treatment | Group A | 65.8 | percentage of patients |
1 to 10 of 63Source ClinicalTrials.gov
See all 63 results by groupParticipant flow27
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| 1st Year | STARTED | Aliskiren | 10,177 | |
| 1st Year | STARTED | ACE-I/ARB | 2,696 | |
| 1st Year | STARTED | No RAS-inhibition | 2,113 | |
| 1st Year | COMPLETED | Aliskiren | 9,120 | |
| 1st Year | COMPLETED | ACE-I/ARB | 2,378 | |
| 1st Year | COMPLETED | No RAS-inhibition | 1,933 | |
| 1st Year | NOT COMPLETED | Aliskiren | 1,057 | |
| 1st Year | NOT COMPLETED | ACE-I/ARB | 318 | |
| 1st Year | NOT COMPLETED | No RAS-inhibition | 180 | |
| 2nd Year | STARTED | Aliskiren | 10,177 |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 participant flowAdverse events1,878
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Left ventricular hypertrophy | Cardiac disorders | Group A | 12 | 10,177 | |
| other | Left ventricular hypertrophy | Cardiac disorders | Group B | 1 | 2,696 | |
| other | Left ventricular hypertrophy | Cardiac disorders | Group C | 2 | 2,113 | |
| other | Atrial fibrillation | Cardiac disorders | Group A | 1 | 10,177 | |
| other | Atrial fibrillation | Cardiac disorders | Group B | 3 | 2,696 | |
| other | Atrial fibrillation | Cardiac disorders | Group C | 0 | 2,113 | |
| other | Blood creatinine increased | Investigations | Group A | 26 | 10,177 | |
| other | Blood creatinine increased | Investigations | Group B | 4 | 2,696 | |
| other | Blood creatinine increased | Investigations | Group C | 1 | 2,113 | |
| other | Blood cholesterol increased | Investigations | Group A | 20 | 10,177 |
1 to 10 of 1,878Source ClinicalTrials.gov
See all 1,878 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group A | ||
| Total, all-cause mortality | Group B | ||
| Total, all-cause mortality | Group C | ||
| Total, other adverse events | Group A | 211 | 10,177 |
| Total, other adverse events | Group B | 41 | 2,696 |
| Total, other adverse events | Group C | 14 | 2,113 |
| Total, serious adverse events | Group A | 649 | 10,177 |
| Total, serious adverse events | Group B | 136 | 2,696 |
| Total, serious adverse events | Group C | 84 | 2,113 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01454583
GET https://conductscience.org/api/trials/v1/NCT01454583/registered?page=2